ClinicalTrials.gg
Active, not recruitingNCT06162572Updated Nov 12, 2026

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

A Phase 1/2 interventional study of S095018 and S095024 in Non-small Cell Lung Cancer (NSCLC), sponsored by Servier Bio-Innovation LLC. Active, not recruiting at 51 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Servier Bio-Innovation LLC · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 12, 2026No longer in Argentina5 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 267 studies in Carcinoma, Non-Small-Cell Lung with a site in Brazil — 53 open to participants now, 124 under way, 91 of them phase 3. Carcinoma, Non-Small-Cell Lung · Brazil.

Enrollment
225th of 254
102 · median 515
Started
2024
with 29 others
Phase 1/2
9 of 267
4 open now
Primary completion
2027-04
later than 53 of 123 live
Registered
208th of 267
by date

Among the 267 studies in Carcinoma, Non-Small-Cell Lung with a site in Brazil, this one is the 225th largest by enrollment of the 254 interventional ones that give a count, is one of 30 that started in 2024, is one of 9 in phase 1/2, reaches primary completion later than 53 of the 123 other live ones, and was the 208th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

53 of the 267 studies in Carcinoma, Non-Small-Cell Lung with a site in Brazil are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Carcinoma, Non-Small-Cell Lung with a site in Brazil, or all of them as a file.
02

Study summary

This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The study includes two parts: part A, the combination-therapy safety lead-in phase to determine the recommended dose for expansion (RDE) for S095018, S095024, and S095029 in combination with cemiplimab and part B, the randomized dose expansion phase to assess the efficacy of S095018, S095024, or S095029 in combination with cemiplimab. Study treatment will be administered for a maximum of 108 weeks, or until confirmed disease progression per iRECIST and/ or until meeting other treatment discontinuation criteria.

03

Conditions studied

  • Non-small Cell Lung Cancer (NSCLC)

Keywords

  • Non-small Cell Lung Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient aged ≥ 18 years
  • Written
  • Histologically (squamous or non-squamous) or documented locally advanced NSCLC not eligible for surgical resection and/or definitive chemoradiation, or NSCLC
  • No prior systemic treatment for locally advanced or metastatic NSCLC
  • High tumor cell expression [Tumor Proportion Score (TPS) ≥50%] based on documented status as determined by an approved test
  • (ECOG) Performance Status of 0 or 1
  • as determined by v1.1

Exclusion criteria

Exclusion Criteria:

  • Tumors harboring driver mutations/genetic aberrations for which targeted therapies are approved as frontline treatment (e.g. EGFR mutation, ALK fusion oncogene, ROS1 aberrations)
  • Prior therapy
  • Active
  • Participants with active and uncontrolled virus (HBV) or virus (HCV) infection
  • Uncontrolled infection. Participants with HIV who have controlled infection (undetectable viral load and above 350 either spontaneously or on a stable antiviral regimen) are allowed to enroll
  • Active, known or suspected disease or immune deficiency
  • History of reactions to any ingredient of the medicinal product (IMP) and other monoclonal antibody (mAbs) and/or their
  • History of interstitial lung disease, idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis or active pneumonitis ≥ grade 2
  • History of inflammatory bowel disease or colitis ≥ grade 2
  • History of hemophagocytic lymphohistiocytosis.
  • Systemic chronic therapy (>10mg/d prednisone or equivalent)
  • infection, as assessed by the investigator
  • Pregnant or breast-feeding (lactating) women
  • Participants with a history of allogeneic organ transplantation (e.g., stem cell or solid organ transplant)
  • Any medical condition that would in the investigator's judgement prevent the participant's participation in the clinical study
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    S095018 (anti-TIM3 antibody) in combination with cemiplimab

    Part A: Combination-therapy safety lead-in

    Drug: S095018 · Drug: Cemiplimab

  • Experimental
    S095024 (anti-CD73 antibody) in combination with cemiplimab

    Part A: Combination-therapy safety lead-in

    Drug: S095024 · Drug: Cemiplimab

  • Experimental
    S095029 (anti-NKG2A antibody) in combination with cemiplimab

    Part A: Combination-therapy safety lead-in

    Drug: S095029 · Drug: Cemiplimab

  • Experimental
    S095018 (anti-TIM3 antibody) RDE in combination with cemiplimab

    Part B: Randomized dose expansion

    Drug: S095018 Recommended Dose Expansion (RDE) · Drug: Cemiplimab

  • Experimental
    S095024 (anti-CD73 antibody) RDE in combination with cemiplimab

    Part B: Randomized dose expansion

    Drug: S095024 RDE · Drug: Cemiplimab

  • Experimental
    S095029 (anti-NKG2A antibody) RDE in combination with cemiplimab

    Part B: Randomized dose expansion

    Drug: S095029 RDE · Drug: Cemiplimab

  • Active comparator
    Cemiplimab (control arm)

    Part B: Randomized dose expansion

    Drug: Cemiplimab

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of dose-limiting toxicities (DLTs) during the first 2 cycles of combination treatment

    Part A

    Time frame: Through the end of the Cycle 2 (each cycle is 21 days)

  2. Incidence and severity of adverse events (AEs)

    Part A

    Time frame: From the signed informed consent form (ICF) to 30 days after the last dose

  3. Incidence and severity of serious adverse events (SAEs)

    Part A

    Time frame: From the signed ICF to 120 days after the last dose

  4. Adverse Events (AEs) Leading to Dose Interruption, Modification, or Delays

    Part A

    Time frame: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)

  5. Adverse Events (AEs) Leading to Permanent Treatment Discontinuation

    Part A

    Time frame: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)

  6. Objective Response (OR)

    Part B: Participants who achieve complete response (CR) or partial response (PR), as per investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: Until study termination (approximately 2 years)

Secondary outcomes

  1. Objective Response (OR)

    Part A: Participants who achieve CR or PR, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator.

    Time frame: Until study termination (approximately 3 years)

  2. Best Overall Response (BOR)

    Part A and B: The best response designation using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST), recorded between the date of the first dose of treatment and the date of the first objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. CR or PR used in the BOR requires a confirmation that is at least 4 weeks apart.

    Time frame: Until study termination (approximately 3 years)

  3. Duration of Response (DoR)

    Part A and B: The time from the first documentation of CR or PR until the documented progressive disease (PD) or death, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator.

    Time frame: Until study termination (approximately 3 years)

  4. Disease Control (DC)

    Part A and B: Participants who achieved stable disease (SD), PR, or CR (based on participant's best response), as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator.

    Time frame: Until study termination (approximately 3 years)

  5. 6-month Durable Response (6-month DR)

    Part A and B: Continuous CR or PR for ≥ 6 months, recorded between the date of the first dose of treatment and the date of the first objectively documented progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or the date of subsequent anti-cancer therapy, whichever occurs first.

    Time frame: Until study termination (approximately 3 years)

  6. Progression-Free Survival (PFS)

    Part A and B: The time from the first dose to the first documented PD or death due to any cause, whichever occurs first, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator.

    Time frame: Until study termination (approximately 3 years)

  7. Plasma or serum concentration of S095018

    Part A and B

    Time frame: From first dose to 30 days after the last dose

  8. Plasma or serum concentration of S095024

    Part A and B

    Time frame: From first dose to 30 days after the last dose

  9. Plasma or serum concentration of S095029

    Part A and B

    Time frame: From first dose to 30 days after the last dose

  10. Incidence and titer of anti-drug antibodies (ADA) directed against S095018

    Part A and B

    Time frame: From screening to 90 days after the last dose

  11. Incidence and titer of anti-drug antibodies (ADA) directed against S095024

    Part A and B

    Time frame: From screening to 90 days after the last dose

  12. Incidence and titer of anti-drug antibodies (ADA) directed against S095029

    Part A and B

    Time frame: From screening to 90 days after the last dose

  13. Incidence and severity of adverse events (AEs)

    Part B

    Time frame: From signed ICF to 30 days after the last dose

  14. Incidence and severity of serious adverse events (SAEs)

    Part B

    Time frame: From signed ICF to 120 days after the last dose

  15. Adverse Events (AEs) Leading to Dose Interruption, Modification, or Delays

    Part B

    Time frame: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)

  16. Adverse Events (AEs) Leading to Permanent Treatment Discontinuation

    Part B

    Time frame: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)

07

Study locations

51 sites
08

References and documents

Individual participant data

Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After Marketing Authorization in EEA or US if the study is used for the approval.

Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

Data sharing details ↗ · clinicaltrials.servier.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Apr 2027, 32 months after the start.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 32 months is below that.

Counting every sponsor, half of 436 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2023
First posted
Dec 8, 2023
StartActual
Aug 7, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Jul 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites removed; no longer in Argentina
Show 5 removed
  • Instituto Médico Especializado Alexander Fleming · Buenos Aires, Argentina
  • Sanatorio Parque S.A. · Santa Fe, Argentina
  • Ordensklinikum Linz Elisabethinen · Linz, Austria
  • Clinica Universitaria de Navarra (Pamplona) · Pamplona, Spain
  • Uz Leuven Campus Gasthuisberg · Leuven, Belgium
across 2 updates, Oct 9, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    1 site removed
    Show 1 removed
    • Uz Leuven Campus Gasthuisberg · Leuven, Belgium
    + 1 other change: verification date
  2. Oct 9, 2026
    4 sites removed; no longer in Argentina
    Show 4 removed
    • Instituto Médico Especializado Alexander Fleming · Buenos Aires, Argentina
    • Sanatorio Parque S.A. · Santa Fe, Argentina
    • Ordensklinikum Linz Elisabethinen · Linz, Austria
    • Clinica Universitaria de Navarra (Pamplona) · Pamplona, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06162572
Lead sponsor
Servier Bio-Innovation LLC
Collaborators
Institut de Recherches Internationales Servier, Regeneron Pharmaceuticals
Responsible party
Sponsor
First posted
Dec 8, 2023
Start date
Aug 7, 2024
Primary completion
Apr 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: SYM-023 · Anti-NKG2A Monoclonal Antibody Sym025

Start the discussion